Albumin-PRF in Sinus Lift With Implants: 2-Year Study

Albumin Platelet-Rich Fibrin in Lateral Sinus Floor Augmentation With Simultaneous Implant Placement: A Prospective Two-Year Follow-Up Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07367217

Enrollment

Registered

2026-01-26

Start date

2023-09-10

Completion date

2025-11-10

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinus Lift Augmentation

Brief summary

thirty-two implants will be inserted in patients seeking implantation of their lost posterior maxillary teeth (premolar and molars) with limited bone height below the floor of the maxillary sinus, secondary to sinus pneumatization. The patients will be selected from those attending the outpatient clinic of the Oral & Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University.

Interventions

PROCEDURElateral sinus lift with using allograft and pericardium membrane

sinus floor elevation with placing allograft and collagen membrane

PROCEDURElateral sinus lift with using exteneded platelet rich fibrin

sinus floor elevation with placing extended-PRF

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patent ostium of maxillary sinus. * Patient with missing one or more posterior maxillary teeth. * Residual bone height of 3-6 mm, measured from the crest of alveolar ridge to the floor of the maxillary sinus at the planned implant site. * A ridge width at the site of implantation of \<5mm. * Platelets of normal range. * Good oral hygiene. * Patients in the age frame between 20 years and 60 years old. * No gender preface in selection of the patients. * A minimum crown height space of 8 mm.

Exclusion criteria

* Active sinusitis, cyst, tumors or root tips at the planned surgical site. * Patients with systemic diseases that contra-indicate the surgical procedure such as uncontrolled diabetes mellitus, bleeding disorders, serious osseous disorders, and mental disorders. * Heavy smoking and alcoholism. * Parafunctional habits such as bruxism and clenching. * Signs of acute infection or pus discharge. * Disturbed occlusion.

Design outcomes

Primary

Measure	Time frame	Description
1. implant stability	12 months	the stability of the implants will be evaluated by RFA with the Osstell Mentor device.
2. Vertical bone height	24 Months	vertical bone height will be measured as the distance from the alveolar crest to the new sinus floor at the middle of the implant

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026